Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates

HM. Lee, R. Andrys, J. Jonczyk, K. Kim, AG. Vishakantegowda, D. Malinak, A. Skarka, M. Schmidt, M. Vaskova, K. Latka, M. Bajda, YS. Jung, B. Malawska, K. Musilek

. 2021 ; 36 (1) : 437-449. [pub] -

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018340

The pyridinium-2-carbaldoximes with quinolinium carboxamide moiety were designed and synthesised as cholinesterase reactivators. The prepared compounds showed intermediate-to-high inhibition of both cholinesterases when compared to standard oximes. Their reactivation ability was evaluated in vitro on human recombinant acetylcholinesterase (hrAChE) and human recombinant butyrylcholinesterase (hrBChE) inhibited by nerve agent surrogates (NIMP, NEMP, and NEDPA) or paraoxon. In the reactivation screening, one compound was able to reactivate hrAChE inhibited by all used organophosphates and two novel compounds were able to reactivate NIMP/NEMP-hrBChE. The reactivation kinetics revealed compound 11 that proved to be excellent reactivator of paraoxon-hrAChE better to obidoxime and showed increased reactivation of NIMP/NEMP-hrBChE, although worse to obidoxime. The molecular interactions of studied reactivators were further identified by in silico calculations. Molecular modelling results revealed the importance of creation of the pre-reactivation complex that could lead to better reactivation of both cholinesterases together with reducing particular interactions for lower intrinsic inhibition by the oxime.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018340
003      
CZ-PrNML
005      
20221025122841.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14756366.2020.1869954 $2 doi
035    __
$a (PubMed)33467931
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Lee, Hyun Myung $u Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea $u Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
245    10
$a Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates / $c HM. Lee, R. Andrys, J. Jonczyk, K. Kim, AG. Vishakantegowda, D. Malinak, A. Skarka, M. Schmidt, M. Vaskova, K. Latka, M. Bajda, YS. Jung, B. Malawska, K. Musilek
520    9_
$a The pyridinium-2-carbaldoximes with quinolinium carboxamide moiety were designed and synthesised as cholinesterase reactivators. The prepared compounds showed intermediate-to-high inhibition of both cholinesterases when compared to standard oximes. Their reactivation ability was evaluated in vitro on human recombinant acetylcholinesterase (hrAChE) and human recombinant butyrylcholinesterase (hrBChE) inhibited by nerve agent surrogates (NIMP, NEMP, and NEDPA) or paraoxon. In the reactivation screening, one compound was able to reactivate hrAChE inhibited by all used organophosphates and two novel compounds were able to reactivate NIMP/NEMP-hrBChE. The reactivation kinetics revealed compound 11 that proved to be excellent reactivator of paraoxon-hrAChE better to obidoxime and showed increased reactivation of NIMP/NEMP-hrBChE, although worse to obidoxime. The molecular interactions of studied reactivators were further identified by in silico calculations. Molecular modelling results revealed the importance of creation of the pre-reactivation complex that could lead to better reactivation of both cholinesterases together with reducing particular interactions for lower intrinsic inhibition by the oxime.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a butyrylcholinesterasa $x metabolismus $7 D002091
650    _2
$a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $7 D002800
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a lidé $7 D006801
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a molekulární struktura $7 D015394
650    _2
$a pyridinové sloučeniny $x chemická syntéza $x chemie $x farmakologie $7 D011726
650    _2
$a chinolinové sloučeniny $x chemická syntéza $x chemie $x farmakologie $7 D011806
650    _2
$a rekombinantní proteiny $x metabolismus $7 D011994
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Andrys, Rudolf $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Jonczyk, Jakub $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
700    1_
$a Kim, Kyuneun $u Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea $u Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
700    1_
$a Vishakantegowda, Avinash G $u Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea $u Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
700    1_
$a Malinak, David $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Skarka, Adam $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Schmidt, Monika $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic $7 xx0278043
700    1_
$a Vaskova, Michaela $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Latka, Kamil $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
700    1_
$a Bajda, Marek $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
700    1_
$a Jung, Young-Sik $u Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea $u Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
700    1_
$a Malawska, Barbara $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
700    1_
$a Musilek, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
773    0_
$w MED00008009 $t Journal of enzyme inhibition and medicinal chemistry $x 1475-6374 $g Roč. 36, č. 1 (2021), s. 437-449
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33467931 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20221025122839 $b ABA008
999    __
$a ok $b bmc $g 1689480 $s 1138784
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 36 $c 1 $d 437-449 $e - $i 1475-6374 $m Journal of enzyme inhibition and medicinal chemistry $n J Enzyme Inhib Med Chem $x MED00008009
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace